Floatz logo

Dapagliflozin

Diabetes Mellitus, Type 2

Bhavya Bhavya, MDSmall moleculePhase 4 / ApprovedActive
BBB
78/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
76/ 100
Competitive Position
81/ 100

Competitive context

141 Active assets in the Diabetes Mellitus, Type 2 cohort.

Asset / SponsorPhaseRating
Liraglutide
RenJi Hospital
Phase 4BBB
Semaglutide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Exenatide
Vivani Medical, Inc
Phase 4BBB
Cotadutide
AstraZeneca
Phase 2BBB
Metformin
Myopharm Limited
Phase 4BBB

View all 50 →

Same molecule, other indications

Dapagliflozin is also rated in:

metabolic dysfunction-associated steatotic liver diseaseDormant
BBB
Indicative ·
77 / 100
View asset →
arteriosclerosis disorderDormant
BBB
Indicative ·
73 / 100
View asset →
diabetes mellitusDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →